ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 294,37
0,00%
Dow Jones
42 342,24
0,04%
DAX
19 999,47
0,00%
Brent Oil
72,15
-0,32%
Bitcoin
97 605,97
0,15%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nuvalent Inc (NUVL)

  7. Nuvalent Inc (NUVL) Actualités

NUVL

Nuvalent (NUVL)

Nuvalent Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NUVL
DateHeureSourceTitreSymboleSociété
19/12/202412h30PR Newswire (US)Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
18/12/202422h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
09/12/202412h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
09/12/202412h30PR Newswire (US)Nuvalent Appoints Grant Bogle to Board of DirectorsNASDAQ:NUVLNuvalent Inc
26/11/202412h52PR Newswire (US)Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
25/11/202422h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NUVLNuvalent Inc
12/11/202412h42Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NUVLNuvalent Inc
12/11/202412h30PR Newswire (US)Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
08/11/202420h17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:NUVLNuvalent Inc
18/09/202422h05PR Newswire (US)Nuvalent Announces Closing of Upsized Public Offering of Common StockNASDAQ:NUVLNuvalent Inc
17/09/202422h13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NUVLNuvalent Inc
17/09/202412h42IH Market NewsInvestors Anticipate Retail Sales Data and Fed Decision; Oil Prices Dip as Investors Weigh U.S. ProductionNASDAQ:NUVLNuvalent Inc
17/09/202404h23PR Newswire (US)Nuvalent Announces Pricing of Upsized Public Offering of Common StockNASDAQ:NUVLNuvalent Inc
16/09/202413h00PR Newswire (US)Nuvalent Announces Public Offering of Common StockNASDAQ:NUVLNuvalent Inc
14/09/202411h00PR Newswire (US)Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development TimelinesNASDAQ:NUVLNuvalent Inc
13/09/202415h53PR Newswire (US)Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655NASDAQ:NUVLNuvalent Inc
09/09/202412h30PR Newswire (US)Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class ProfilesNASDAQ:NUVLNuvalent Inc
29/08/202412h30PR Newswire (US)Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
08/08/202412h30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
22/07/202412h30PR Newswire (US)Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective InhibitorNASDAQ:NUVLNuvalent Inc
16/07/202412h30PR Newswire (US)Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024NASDAQ:NUVLNuvalent Inc
11/07/202422h45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
11/07/202412h30PR Newswire (US)Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific OfficerNASDAQ:NUVLNuvalent Inc
29/05/202412h30PR Newswire (US)Nuvalent to Participate in the 2024 Jefferies Global Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
16/05/202422h01PR Newswire (US)Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655NASDAQ:NUVLNuvalent Inc
09/05/202412h30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
08/04/202422h30PR Newswire (US)Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
05/03/202422h52PR Newswire (US)Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
27/02/202413h00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NUVLNuvalent Inc
27/02/202412h42Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NUVLNuvalent Inc
 Showing the most relevant articles for your search:NASDAQ:NUVL

Dernières Valeurs Consultées

NYSE
NKE
Nike
EU
CAP
Capgemini
EU
PX4
SBF 120
EU
LR
Legrand
COIN
ETHUSD
Ethereum
NYSE
KO
Coca Cola
EU
AI
Air Liquide
COIN
SOLUSD
Solana
COIN
ADAUSD
Cardano
EU
ACA
Credit Agricole
EU
DG
Vinci
COIN
DOGEUSD
Dogecoin
NASDAQ
NVDA
NVIDIA
EU
ML
Michelin
EU
ORA
Orange
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés